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ABSTRACT 
Objective: The present study was undertaken to evaluate the acute and chronic anxiolytic effects of nifedipine in comparison to diazepam using in 
Swiss Albino mice using two behavioral models. 
Methods: 30 Swiss albino mice were divided into 5 groups with 6 mice in each group. The study was conducted in two phases to evaluate acute and 
chronic effects. The groups consisted of diazepam (1 mg/kg), 3 doses of nifedipine (2.6 mg/kg, 5.2 mg/kg and 10.4 mg/kg) and vehicle control. The 
Elevated Plus Maze (EPM) and Light and Dark box were used to evaluate the anti-anxiety effects. The number of entries and time spent in the open 
arm of the elevated plus-maze and in the light area of light and dark box model were noted and compared among the 5 groups. Observations were 
analyzed using ANOVA and post hoc Tukey's test. 
Results: Nifedipine (5.2 mg/kg and 10.4 mg/kg) significantly increased the number of entries and time spent in the open arm compared to vehicle 
control in the EPM test (p<0.001). Similarly, in the light and dark box test, nifedipine (5.2 mg/kg and 10.4 mg/kg) increased the number of entries and 
time spent in the light area compared to vehicle control (p<0.05). However, the low dose of nifedipine (2.6 mg/kg) did not exhibit significant findings. 
Conclusion: Two doses of nifedipine (5.2 mg/kg and 10.4 mg/kg) possess anti-anxiety effects both on acute and chronic administration in both 
elevated plus maze and light and dark box model.  
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INTRODUCTION 
Anxiety is a phenomenon characterized by uneasiness, 
apprehension, fear, or worry, which at times occurs without any 
identifiable triggering stimuli [1]. Anxiety disorders are among the 
most common mental, emotional, and behavioral problems and 
affect one-eighth of the total population worldwide [2] with a global 
prevalence of 7·3% and they have a substantial negative impact on 
the quality of life [3]. Hence treatment of anxiety is an important 
area of research interest in psychopharmacology. 
Approximately two-thirds of the anxious patients respond to the 
currently available treatments, but the magnitude of improvement is 
still disappointing; besides, they also produce various systemic side 
effects and exhibit dependence and tolerance on chronic treatment 
which now have become a major concern about the use of currently 
used medicines [4]. 
Pharmacotherapy for anxiety disorders mainly includes the use of 
benzodiazepines, but regular use leads to deterioration of cognitive 
functioning, psychomotor impairment, amnesia, physical 
dependence and tolerance. Due to the lack of an ideal anxiolytic 
drug, the search for better anxiolytic drugs continue [5]. 
In the central nervous system, neurotransmitters responsible for the 
occurrence of symptoms of anxiety disorders include 
norepinephrine, serotonin, dopamine and gamma-aminobutyric acid 
(GABA) [6]. Neurotransmitter release involves the activation of 
voltage-gated calcium channels; hence it can be postulated that 
calcium channel antagonists (CCA) might inhibit the entry of calcium 
into the cells, thereby inhibiting its role as an intracellular 
messenger and exerting anti-anxiety [7]. 
Dihydropyridines (DHPs) cross the blood-brain barrier to varying 
extents and reach the central nervous system in sufficient quantities 
to bring about centrally mediated effects [8]. DHPs, namely 
nifedipine, nimodipine and nitrendipine are more extensively taken 
up into the brain from the blood [9]. Previous studies in rodents 
have demonstrated conflicting results for the anxiolytic activity of 
dihydropyridines and benzothiazepines using various behavioral 
models [10-12]. CCAs are devoid of the side effects seen with 
anxiolytic drugs like sedation, cognitive impairment and dependence 
[13]. Thus, the use of CCAs in patients with anxiety disorders can 
lead to fewer side effects as compared to anxiolytics.  
Hence in this study, we aimed at determining the antianxiety 
property of nifedipine since it is one of the most commonly 
prescribed CCA in India [14, 15], using 2 behavioral models, namely 
Elevated Plus maze and Light and Dark box. 
MATERIALS AND METHODS 
The study was initiated after receiving necessary approvals from the 
Institutional Animal Ethics committee of our institute in accordance 
with CPCSEA (Approval No–IAEC/01/2017). The duration of the 
study was 6 mo conducted between March 2018 to August 2018. 
Experimental animals 
A total of 30 male Swiss Albino mice were procured from a registered 
breeder (Bombay Veterinary College, Parel Mumbai). The age and 
weight of the mice ranged from 6 to 8 w and between 20–30 grams, 
respectively. The mice were group-housed in steel cages with 
adequate bedding material and allowed to have food and water ad 
libitum. The temperature was maintained at 23 °C-25 °C with a 40–
50% humidity and 12 h light/12 h dark cycle during the experiment. 
The experiment was performed between 0900 to 0200 h. screening for 
healthy albino mice with normal behavior and activity was done. 
Chemical and drugs  
1% w/v carboxymethylcellulose was procured from the 
experimental laboratory of our institute, diazepam (1 mg/kg) from 
Centaur Pharmaceuticals Ltd and nifedipine from Sun Pharma Pvt 
Ltd. The doses for nifedipine and diazepam were extrapolated from 
human doses of the drug [16, 17]. 
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Experimental design and procedure  
30 male swiss albino mice weighing between 20–30 grams were 
randomly divided into five groups of six mice each. Prior to the 
experiment, the animals were introduced in both the models to 
familiarize them with the model environment. Details are given in 
table 1. 
The study was carried out in two phases. Mice were subjected to 
elevated plus maze followed by light and dark box to evaluate the 
acute anxiolytic effect of nifedipine after a single administration. 
This was followed by administering nifedipine for 30 d to evaluate 
the chronic anxiolytic effects using the same behavioural models. 
Elevated plus-maze model 
It is an unconditioned behavioral model used to assess the anxiolytic 
activity in mice [18]. Rodents generally tend to avoid open spaces 
and stay in darker areas. When the animal is placed on the EPM, 
animals with anxious behavior spend more time in enclosed arms 
than open arms.  
The apparatus consists of two open arms and two closed arms with an 
open roof and elevated to a height of 50 cm above the floor. Thirty mins 
after oral administration of the test drug or standard, each mouse was 
placed in the centre of the maze facing one of the enclosed arms and was 
observed for 5 min. Entry into the arm was indicated by all four paws 
including the tail of the mouse into the arm. After 5 min of observation, 
the total number of entries in open arm and time spent in the open arm 
was noted. The maze was cleaned after each trial [19]. 
Light and dark box model 
This is another model used to assess the anxiolytic activity in mice 
based on the inherent aversion to lit areas [20]. The apparatus 
consists of an open-top wooden box with two chambers separated 
by a partition wall and connected by a small opening in the center of 
the wall. The mouse was placed at the center of the brightly lit arena 
of the light and dark box. The transition between the light and dark 
box and the time spent in the light area were recorded for 10 min. 
Animals spend more time in the light chamber and show more 
locomotor activity after treatment with anxiolytics. 
  
Table 1: Description of group and drugs administered during the study (n=30) 
Group Group description No. Of animals Dose 
I 1% CMC (Vehicle Control) 6 0.5 ml (PO) 
II Diazepam (Positive Control) 6 1 mg/kg (PO) 
III Nifedipine (low dose) 6 2.6 mg/kg (PO) 
IV Nifedipine (medium dose) 6 5.2 mg/kg (PO) 
V Nifedipine (high dose) 6 10.4 mg/kg (PO) 
PO–Per Oral 
 
Statistical analysis  
Data was represented as mean±SD. Data were analyzed using one-
way analysis of variance (ANOVA) for between-group comparison 
followed by post-hoc Tukey's test. A p-value of<0.05 was considered 
statistically significant. GraphPad Instat version 3 was the statistical 
software used for analysis. 
RESULTS 
Two models, namely elevated plus maze and light and dark box 
model were used for evaluation of the anxiolytic activity of 
nifedipine in swiss albino mice. 
Evaluation of acute anxiolytic effect 
Elevated plus-maze model  
In this model, efficacy was measured by an increase in the number of 
open arm entries and time spent in open arms between the groups.  
Light and dark box model 
In this model, efficacy was measured by an increase in the mean 
values of the 2 parameters i.e. the number of entries into the light 
area and the time spent in the light area of the Light-Dark box 
apparatus. 
The results of both models are tabulated in table 2. 
On performing a one-way analysis of variance (ANOVA) between 
groups in both models, the p-value was<0.001, which is highly 
significant. On post–hoc Tukey's comparison, there was a 
statistically significant difference between the number of open 
arm entries and entry into light area in the diazepam [1 mg/kg] 
group, medium and high doses of nifedipine [5.2 mg/kg and 10.4 
mg/kg] compared to the vehicle control group (p<0.001). 
However, the difference between diazepam [1 mg/kg] and medium 
and high dose nifedipine [5.2 mg/kg and 10.4 mg/kg, respectively] 
was not statistically significant for time spent in open arm and 
light area. 
Evaluation of the chronic anxiolytic effect  
The animals were administered the test drug and control orally daily 
for 30 d and the anxiolytic activity of nifedipine was evaluated using 
the behavioral models. Results of the elevated plus-maze model and 
light and dark box model are given in table 3. 
 
Table 2: Comparison of the number of entries and time spent in open arm and light area in elevated plus maze and light and dark box 
model (Acute effect) 
 Elevated plus maze model  Light and dark box model 
Group 
no. 
Group description No. of open arm 
entries 
Time spent in open arm 
(min) 
No. of entries in light 
area 
Time spent in light area 
(min) 
1 Vehicle Control 
(0.5 ml 1% CMC p. o.) 
4.35±0.35 1.26±0.63 2.33±0.81 5.14±0.37 
2 Diazepam  
(1 mg/kg p. o.) 
8.33±1.41* 3.19±0.55* 6.33±1.36* 7.34±0.48* 
3 Nifedipine  
(2.6 mg/kg p. o.) 
5.16±1.03# 1.66±0.30# 3.66±1.21# 4.06±0.70# 
4 Nifedipine  
(5.2 mg/kg p. o.) 
7.16±1.26* 3.09±0.45*$ 5.16±0.75* 6.90±0.49*$ 
5 Nifedipine  
(10.4 mg/kg p. o.) 
8.16±1.16* 2.75±0.49*$ 5.83±0.75* 7.58±0.60*$ 
Values are expressed as mean±SD.*p value<0.001 as compared to control, #p value<0.01 as compared to diazepam. $p value<0.01 as compared to 
low dose nifedipine [2.6 mg/kg] 
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Table 3: Comparison of the number of entries and time spent in open arm and light area in Elevated plus maze and light and dark box 
model (Chronic effect) 
  Elevated plus-maze model Light and dark box model 
Group 
no. 
Group description No. of open arm 
entries 
Time spent in open arm 
(min) 
No. of entries in light 
area 
Time spent in light area 
(min) 
1 Vehicle Control 
(0.5 ml 1%CMC p. o) 
4.33±1.03 1.29±0.19 3.33±0.81 2.40±1.02 
2 Diazepam  
(1 mg/kg p. o) 
7.83±0.98* 3.24±0.41* 6.16±0.75* 6.92±0.34* 
3 Nifedipine  
(2.6 mg/kg p. o) 
5.16±0.75# 1.39±0.38# 3.50±1.04# 3.85±0.56*# 
4 Nifedipine  
(5.2 mg/kg p. o) 
7.16±0.75*$ 2.78±0.60*$ 4.83±0.75* 4.71±0.41* 
5 Nifedipine  
(10.4 mg/kg p. o) 
8.16±0.75*$ 3.30±0.18*$ 5.83±0.98*$ 6.50±0.69*$ 
Values are expressed as Mean+SD.*p value<0.001 compared to vehicle control. #p value<0.001 as compared to diazepam. $p value<0.01 as compared 
to low dose nifedipine [2.6 mg/kg]. 
 
When compared to the control group, nifedipine showed significant 
anxiolytic activity after 30 d of administration at medium (5.2 
mg/kg) and high dose (10.4 mg/kg) by showing an increase in the 
number of entries in the open arm and light area. There was also an 
increase in the time spent in open arms and light area following drug 
administration. This shows that nifedipine had a chronic anxiolytic 
effect after 30 d of drug administration. 
DISCUSSION 
Anxiety, like all emotions, has cognitive, neurobiological and 
behavioural components. It is a negative emotion that is felt in 
response to perceived threats coming from internal or external 
sources which may or may not be real [21]. 
The proposed mechanism of the anxiolytic activity of calcium channel 
antagonist is the drugs that cross the blood-brain barrier (nifedipine, 
nimodipine, nitrendipine) reach at higher concentrations to the limbic 
system, comprising of the hippocampus and amygdala [22]. A 
neurocircuit that arises from the output pathways of the central 
nucleus of the amygdala mediates fear and anxiety responses in 
humans. Exaggerated output through the amygdala related circuits 
may be the underlying cause for the various types of anxiety disorders 
[23]. Binding studies reveal that the amygdala in the brain also 
contains binding sites for dihydropyridines, which explains its 
involvement in anxiolytic activity [24].  
Calcium plays an important role in the release of multiple 
neurotransmitters such as serotonin (5-HT), acetylcholine (Ach), 
noradrenaline and dopamine from nerve terminals and dendrites in 
the CNS. Hence, it can be hypothesized that a calcium channel 
antagonist will block the action of these neurotransmitters by 
preventing their release. An imbalance in the neurotransmitters, 
mainly serotonin, noradrenaline and GABA, has been implicated in the 
pathogenesis of anxiety disorders, hence drugs that block the release 
of these neurotransmitters potentially possess anxiolytic activity [25].  
In this study, elevated plus maze and light and dark box models were 
used to assess the anxiolytic activity of nifedipine. Swiss albino mice 
inherently show aversion to light, high and open spaces, and hence 
spend more time in enclosed or dark spaces. An anxiolytic drug 
specifically increases the number of entries and total time spent in 
open arm and light area. This behavioral activity forms the basis of 
its use as a screening model for anti-anxiety effects. 
The present study indicated that both medium and high doses of 
nifedipine (5.2 mg/kg and 10.4 mg/kg, respectively) showed 
anxiolytic activity in mice when evaluated using both elevated plus 
maze and light and dark box models. The first part was performed 
where the anxiolytic effect of nifedipine was determined after a 
single dose oral administration of nifedipine at 3 doses. Followed by 
a daily administration of nifedipine for 30 d to determine a chronic 
anxiolytic effect. Nifedipine showed a dose-dependent anxiolytic 
effect in both the elevated plus maze model and the light and dark 
box model. 
Similar findings were reported by Ganouni et al. who evaluated the 
anxiolytic effect of increasing doses of nifedipine (1.25 mg/kg, 2.5 
mg/kg and 5 mg/kg) using water consumption in a novel 
environment model as the behavioral model. A dose-dependent 
increase in the anxiolytic activity was seen [10]. Another study 
conducted by Tanwani et al. evaluated the anti-anxiety, anti-
depressant and sedative effects of nimodipine in swiss albino mice 
using the elevated plus-maze model to evaluate the anxiolytic 
effects, they found that a low dose of nimodipine (2.5 mg/kg) had 
anti-anxiety effects [12]. 
Anxiety disorders are closely associated with the development of 
hypertension and vice versa. Moreover, anxiety is one of the barriers 
in the treatment of hypertension [26]. ACE inhibitors and calcium 
channel antagonists are one of the first-line drugs used in the 
management of hypertension. Hence anti-hypertensive agents that 
have an anxiolytic effect may help in the management of anxiety 
along with hypertension and at the same time avoid side effects like 
sedation, impairment of consciousness and dependence seen with 
typical anxiolytics. Another advantage of nifedipine is that it does 
not lower the blood pressure in normotensive individuals, making it 
an appropriate choice for an anxiolytic calcium channel antagonist in 
the future.  
The limitations of our study are small sample size and the 
combination of low dose nifedipine with diazepam was not 
evaluated to test the potentiation of anxiolytic activity. Further, in 
vitro studies to test for the levels of the drugs in the brain tissues are 
needed to add more value to the pharmacodynamic evidence 
obtained from the current study. The greatest opportunity for the 
screening of repurposed drugs like nifedipine as an anxiolytic is that 
the claimed mechanism has not yet been adequately addressed. The 
detection of an already marketed drug with a novel anxiolytic 
mechanism would be a significant step forward. 
CONCLUSION 
Our study suggests that medium (5.2 mg/kg) and high dose (10.4 
mg/kg) of nifedipine has considerable anxiolytic activity comparable 
to diazepam and more effective than vehicle control in behavioural 
models on acute and chronic administration, possibly due to the 
presence of dihydropyridine receptors on the amygdala which is the 
centre responsible for anxiety. The anxiolytic property of nifedipine 
will enhance its therapeutic utility and improve the quality of life of 
patients with anxiety. Hence with further clinical studies, nifedipine 
can be effectively used in hypertension, which is often associated with 
anxiety. 
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